Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001104659-25-019184
Filing Date
2025-02-28
Accepted
2025-02-28 16:37:17
Documents
6

Document Format Files

Seq Description Document Type Size
1 FORM S-3 tm257774d1_s3.htm S-3 201998
2 EXHIBIT 5.1 tm257774d1_ex5-1.htm EX-5.1 10541
3 EXHIBIT 23.1 tm257774d1_ex23-1.htm EX-23.1 2488
4 EX-FILING FEES tm257774d1_ex-filingfees.htm EX-FILING FEES 16262
5 GRAPHIC tm257774d1_ex5-1img001.jpg GRAPHIC 2566
6 GRAPHIC tm257774d1_s3img001.jpg GRAPHIC 5565
  Complete submission text file 0001104659-25-019184.txt   243950
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: S-3 | Act: 33 | File No.: 333-285438 | Film No.: 25691091
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)